Merck Sharp & Dohme LLC
Tulisokibart
Hidradenitis Suppurativa
Countdown
132days
Phase 2 readout · Nov 16, 2026
What's at stake
Phase 2 trial results for Tulisokibart in Hidradenitis Suppurativa are due Nov 16, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 14h ago
“CT.gov NCT06956235: Phase 2 trial, sponsor Merck Sharp & Dohme LLC, drug Tulisokibart. Primary completion date 2026-11-16 (estimated).”